{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:26:18Z","timestamp":1791300378541,"version":"4.1.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with chronic myeloproliferative neoplasms, including essential thrombocythemia (ET), polycythemia vera (PV), and chronic myeloid leukemia (CML), are at increased risk of new hematologic malignancies, but their risk of nonhematologic malignancies remains unknown. In the present study, we assessed the risk of both types of malignancies after an ET, PV, or CML diagnosis. We linked 2 population-based nationwide registries, the Danish National Registry of Patients, covering all Danish hospitals and the Danish Cancer Registry, and assessed subsequent cancer risk in a cohort of all 7229 patients diagnosed with a chronic myeloproliferative neoplasm during 1977-2008. We compared the incidence of subsequent cancer in this cohort with that expected on the basis of cancer incidence in the general population (standardized incidence ratio). Overall, ET, PV, and CML patients were at increased risk of developing both new hematologic and nonhematologic cancers. The standardized incidence ratio for developing a nonhematologic cancer was 1.2 (95% confidence interval [95% CI]): 1.0-1.4) for patients with ET, 1.4 (95% CI: 1.3-1.5) for patients with PV, and 1.6 (95% CI: 1.3-2.0) for patients with CML. We conclude that patients with chronic myeloproliferative neoplasms are at increased risk of developing a new malignant disease.<\/jats:p>","DOI":"10.1182\/blood-2011-04-348755","type":"journal-article","created":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T22:23:41Z","timestamp":1319840621000},"page":"6515-6520","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":149,"title":["Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study"],"prefix":"10.1182","volume":"118","author":[{"given":"Henrik","family":"Frederiksen","sequence":"first","affiliation":[{"name":"Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark;"},{"name":"Department of Hematology, Odense University Hospital, Odense, Denmark; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ra K\u00f6rmendin\u00e9","family":"Farkas","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Fynbo","family":"Christiansen","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Carl","family":"Hasselbalch","sequence":"additional","affiliation":[{"name":"Department of Hematology, Roskilde Hospital, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Toft","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111807013138400_B1","article-title":"International Agency for Research on Cancer.","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Swerdlow","year":"2008"},{"issue":"5","key":"2019111807013138400_B2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","article-title":"Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders.","volume":"22","author":"Cervantes","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"2019111807013138400_B3","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111807013138400_B4","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.1950.02910290018005","article-title":"Physiopathology and course of polycythemia vera as related to therapy.","volume":"142","author":"Dameshek","year":"1950","journal-title":"J Am Med Assoc"},{"issue":"7","key":"2019111807013138400_B5","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1055-9965.EPI-09-0353","article-title":"Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.","volume":"18","author":"Vannucchi","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"2019111807013138400_B6","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/aje\/kwq262","article-title":"Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study.","volume":"172","author":"Rebora","year":"2010","journal-title":"Am J Epidemiol"},{"key":"2019111807013138400_B7","article-title":"Higher risk of primary cancers after polycythaemia vera and vice versa [published online ahead of print].","author":"Fallah","journal-title":"Br J Haematol"},{"issue":"5462","key":"2019111807013138400_B8","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1126\/science.287.5462.2398","article-title":"Epidemiology. When an entire country is a cohort.","volume":"287","author":"Frank","year":"2000","journal-title":"Science"},{"issue":"3","key":"2019111807013138400_B9","first-page":"263","article-title":"The Danish National Hospital Register. A valuable source of data for modern health sciences.","volume":"46","author":"Andersen","year":"1999","journal-title":"Dan Med Bull"},{"issue":"3","key":"2019111807013138400_B10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00008469-200506000-00002","article-title":"The data quality of haematological malignancy ICD-10 diagnoses in a population-based hospital discharge registry.","volume":"14","author":"N\u00f8rgaard","year":"2005","journal-title":"Eur J Cancer Prev"},{"issue":"5","key":"2019111807013138400_B11","first-page":"535","article-title":"The Danish Cancer Registry\u2013history, content, quality and use.","volume":"44","author":"Storm","year":"1997","journal-title":"Dan Med Bull"},{"key":"2019111807013138400_B12","first-page":"1","article-title":"Statistical methods in cancer research. Volume II\u2013The design and analysis of cohort studies.","volume":"82","author":"Breslow","year":"1987","journal-title":"IARC Sci Publ"},{"issue":"6","key":"2019111807013138400_B13","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1378\/chest.07-2543","article-title":"Impact of COPD on outcome among patients with complicated peptic ulcer.","volume":"133","author":"Christensen","year":"2008","journal-title":"Chest"},{"issue":"14","key":"2019111807013138400_B14","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2009-07-235119","article-title":"Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.","volume":"115","author":"Thoennissen","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111807013138400_B15","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2019111807013138400_B16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.","volume":"304","author":"Berk","year":"1981","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111807013138400_B17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111807013138400_B18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1179\/102453308X316022","article-title":"Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.","volume":"13","author":"Radaelli","year":"2008","journal-title":"Hematology"},{"issue":"7","key":"2019111807013138400_B19","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V89.7.2319","article-title":"Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group.","volume":"89","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"2019111807013138400_B20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/bjc.1981.150","article-title":"Treament of polycythemia vera by radiophosphorus or busulphan: A randomized trial.","volume":"44","author":"Haanen","year":"1981","journal-title":"Br J Cancer"},{"issue":"1","key":"2019111807013138400_B21","first-page":"9","article-title":"Association of renal carcinoma and polycythemia vera: 5 cases in which nephrectomy preceded and did not influence the clinical course of the polycythemia.","volume":"33","author":"Najean","year":"1991","journal-title":"Nouv Rev Fr Hematol"},{"issue":"2","key":"2019111807013138400_B22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jaad.2003.11.059","article-title":"Hydroxyurea-associated squamous dysplasia.","volume":"51","author":"Sanchez-Palacios","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"2019111807013138400_B23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"2019111807013138400_B24","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","article-title":"Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"2019111807013138400_B25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MOU.0b013e328277f180","article-title":"Prognostic markers in renal cell carcinoma.","volume":"17","author":"Ljungberg","year":"2007","journal-title":"Curr Opin Urol"},{"issue":"23","key":"2019111807013138400_B26","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9754","key":"2019111807013138400_B27","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"2019111807013138400_B28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jnci\/djh118","article-title":"Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study.","volume":"96","author":"S\u00f8rensen","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2019111807013138400_B29","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/ijc.24439","article-title":"Cancer incidence and risk factors after solid organ transplantation.","volume":"125","author":"Vajdic","year":"2009","journal-title":"Int J Cancer"},{"issue":"6","key":"2019111807013138400_B30","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"11","key":"2019111807013138400_B31","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/25\/6515\/1346342\/zh805111006515.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/25\/6515\/1346342\/zh805111006515.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T07:04:46Z","timestamp":1574060686000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/25\/6515\/29262\/Chronic-myeloproliferative-neoplasms-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,15]]},"references-count":31,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2011,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-04-348755","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,15]]}}}